Hyperhomocysteinemia and thrombosis: An overview

Archives of Pathology and Laboratory Medicine

Volumn 131, Issue 6, 2007, Pages 872-884

  Eldibany, Mohamed M ^a,b   Caprini, Joseph A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Evanston Northwestern Healthcare ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5 LEIDEN; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE;

ARTERY THROMBOSIS; ATHEROSCLEROSIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; DISEASE CLASSIFICATION; HUMAN; HYPERHOMOCYSTEINEMIA; PATHOGENESIS; REVIEW; THROMBOPHILIA; THROMBOSIS; VASCULAR DISEASE; VENOUS THROMBOEMBOLISM; VITAMIN SUPPLEMENTATION;

HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); THROMBOEMBOLISM;

EID: 34250333053     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Review

References (211)

1. Butz LW, Du Vigneaud V. Formation of a homologue of cystine by the decomposition of methionine with sulfuric acid. J Biol Chem. 1932;99:135-142.
2. McCully KS. Vascular pathology of homocysteinemia; implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969;56:111-128.
3. Selhub J. Homocysteine metabolism. Annu Rev Nutr. 1999;19:217-246.
4. Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem. 1990;1:228-237.
5. Garrow TA, Millian NS, Park EL, et al. The influence of nutrition on rat liver betaine-homocysteine methyltransferase expression and preliminary characterization of recombinant human BHMT as a zinc metalloenzyme. In: Mato JM, Caballero A, eds. Proceedings of the 4th Workshop on Methionine Metabolism. Madrid, Spain: Consejo Superior de Investigaciones Cientificas Publishers; 1998:63-76.
6. Rozen R. Methylenetetrahydrofolate reductase in vascular disease, neural tube defects and colon cancer. In: Mato JM, Caballero A, eds. Proceedings of the 4th Workshop on Methionine Metabolism. Madrid, Spain: Consejo Superior de Investigaciones Cientificas Publishers; 1998:51-61.
7. Finkelstein JD, Kyle WE, Harris B. Methionine metabolism in mammals: regulatory effects of S-adenosylhomocysteine. Arch Biochem Biophys. 1974;165:774-779.
8. Finkelstein JD, Martin JJ, Harris BJ. Methionine metabolism in mammals: the methionine-sparing effects of cystine. J Biol Chem. 1988;263:11750-11754.
9. Finkelstein JD, Mudd SH. Transsulfuration in mammals. The methionine sparing effect of cysteine. J Biol Chem. 1967;242:873-880.
10. McKeever MP, Weir DG, Molloy A, Scott JM. Betaine-homocysteine methyltransferase: organ distribution in man, pig and rat and subcellular distribution in the rat. Clin Sci. 1991;81:551-556.
11. Christensen B, Refsum H, Vintermyr O, Ueland PM. Homocysteine export from cells cultured in the presence of physiological or superfluous levels of methionine: methionine loading of nontransformed, transformed, proliferating, and quiescent cells in culture. J Cell Biol. 1999;146:52-62.
12. Ueland PM, Refsum H, Male R, Lillehaug JR. Disposition of endogenous homocysteine by mouse fibroblast C3H/10T1/2 Cl 8 and the chemically transformed C3H/10T1/2 MCA Cl 16 cells following methotrexate exposure. J Natl Cancer Inst. 1986;77:283-289.
13. Rozen R. Genetic modulation of homocysteinemia. Semin Thromb Hemost. 2000;26:255-261.
14. 12 and folic metabolism: folic acid clearance studies. J Clin Invest. 1962;41:1263-1276.
15. Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease. New York, NY: McGraw-Hill; 1995:1279-1327.
16. Kraus JP, Miroslav J, Viktor K, et al. Cystathionine B-synthase mutations in homocystinuria. Hum Mutat. 1999;13:362-375.
17. Rosenblatt DS. Inherited disorders of folate transport and metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 7th ed. New York, NY: McGraw-Hill; 1995:3111-3128.
18. Mudd SH, Uhlendorf BW, Freeman JM, Finkelstein JD, Shih VE. Homocystinuria associated with decreased methylenetetrahydrofolate reductase activity. Biochem Biophys Res Commun. 1972;46:905-912.
19. Shih VE, Salam MZ, Mudd SH, Uhlendorf BW, Adams RD. A new form of homocystinuria due to 5,10-methylenetetrohydrofolate reductase deficiency. Pediatr Res. 1972;6:395.
20. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease. A common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111-113.
21. Goyette P, Frosst P, Rosenblatt DS, Rozen R. Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in severe MTHFR deficiency. Am J Hum Genet. 1995;56:1052-1059.
22. Goyette P, Christensen B, Rosenblatt DS, Rozen R. Severe and mild mutations in cis for the methylenetetrahydrofolate reductase MTHFR) gene, and description of 5 novel mutations in MTHFR. Am J Hum Genet. 1996;59:1268-1275.
23. van der Put NMJ, Gabreels F, Stevens EMB, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet. 1998;62:1046-1051.
24. Viel A, Dall'Agnese I, Simone F, et al. Loss of heterozygosity at the 5,10-methylenetetrahydrofolate reductase locus in human ovarian carcinomas. Br J Cancer. 1997;75:1105-1110.
25. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab. 1998;64:169-172.
26. Kang S-S, Wong PWK, Susmano A, et al. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary disease. Am J Hum Genet. 1991;48:536-545.
27. Christensen B, Frosst P, Lussier-Cacan S, et al. Correlation of a common mutation in the methylenetetrahydrofolate reductase (MTHFR) gene with plasma homocysteine in patients with premature coronary artery disease. Arterioscler Thromb Vasc Biol. 1997;17:569-573.
28. van der Put NMJ, Steegers-Theunissen RPM, Frosst P, et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet. 1995;346:1070-1071.
29. Goyette P, Sumner JS, Milos R, et al. Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nat Genet. 1994;7:195-200.
30. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 1996;93:7-9.
31. Ma J, Stampfer MJ, Hennekens CH, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in U.S. physicians. Circulation. 1996;94:2410-2416.
32. Weisberg IS, lacques PF, Selhub J, et al. The 1298A→C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. Atherosclerosis. 2001;156:409-415.
33. Shaw GM, Rozen R, Finnell RH, Wasserman CR, Lammer EJ. Maternal vitamin use: genetic variation of infant methylenetetrahydrofolate reductase and risk for spina bifida. Am J Epidemiol. 1998;148:30-37.
34. Motulsky AG. Nutritional ecogenetics: homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid. Am J Hum Genet. 1996;58:17-20.
35. Engbersen AM, Franken DG, Boers GH, Stevens EM, Trijbels FJ. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet. 1995;56:142-150.
36. Guttormsen AB, Ueland PM, Nesthus I, et al. Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (≥ 40 μmol/liter). J Clin Invest. 1996;98:2174-2183.
37. Harmon DL, Woodside JV, Yarnell JWG, et al. The common "thermolabile" variant of methylenetetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. Q J Med. 1996;89:571-577.
38. Deloughery TG, Evans A, Sadeghi A, et al. Common mutation in methylenetetrahydrofolate reductase. Correlation with homocysteine metabolism and late-onset vascular disease. Circulation. 1996;94:3074-3078.
39. Malinow MR, Niero FJ, Kruger WD, et al. The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arterioscler Thromb Vasc Biol. 1997;17:1157-1162.
40. Arruda VR, von Zuben PM, Chiaparini LC, Annichino-Bizzacchi JM, Costa FF. The mutation Ala677→Val in the methylenetetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. Thromb Haemost. 1997;77:818-821.
41. Kluijtmans LAJ, van den Heuvel LP, Boers GHJ, et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet. 1996;58:35-41.
42. Goyette P, Rosenblatt D, Rozen R. Homocystinuria (methylenetetrahydrofolate reductase deficiency) and mutation of factor V gene. J Inherit Metab Dis. 1998;21:690-691.
43. Mandel H, Brenner B, Berant M, et al. Coexistence of hereditary homocystinuria and factor V Leiden: effect on thrombosis. N Engl J Med. 1996;334:763-768.
44. Whitehead AS, Gallagher P, Mills JL, et al. A genetic defect in 5,10 methylenetetrahydrofolate reductase in neural tube defects. Q J Med. 1995;88:763-766.
45. van der Put NMJ, Eskes TKAB, Blom HJ. Is the common 677C-T mutation in the methylenetetrahydrofolate reductase gene a risk factor for neutral tube defects? A meta-analysis. Q J Med. 1997;90:111-115.
46. Shields DC, Kirke PN, Mills JL, et al. The thermolabile variant of methylenetetrahydrofolate reductase and neural tube defects: an evaluation of genetic risk and the relative importance of the genotypes of the embryo and the mother. Am J Hum Genet. 1999;64:1045-1055.
47. Czeizel AE, Dudas I. Prevention of the first occurrence of neural tube defects by periconceptional vitamin supplementation. N Engl J Med. 1992;327:1832-1835.
48. MRC, Vitamin Study Research Group. Prevention of neural-tube defects: results of the Medical Research Council vitamin study. Lancet. 1991;332:1120-1121.
49. Grandone E, Margaglione M, Colaizzo D, et al. Factor V Leiden, C→T MTHFR polymorphism and genetic susceptibility to preeclampsia. Thromb Haemost. 1997;77:1052-1054.
50. Kupferminc MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med. 1999;340:9-13.
51. Nelen WLDM, Steegers EAP, Eskes TKAB, Blom HJ. Genetic risk factor for unexplained recurrent early pregnancy loss. Lancet. 1997;350:861.
52. Sohda S, Arinami T, Hamada H, et al. Methylenetetrahydrofolate reductase polymorphism and pre-eclampsia. J Med Genet. 1997;34:525-526.
53. 6:4862-4864.
54. Ma J, Sfampfer MJ, Giovannucci E, et al. Methylenetetrahydrofolate reductase polymorphism, reduced risk of colorectal cancer and dietary interactions. Cancer Res. 1997;57:1098-1102.
55. Pereira P, Stanton V, Jothy S, et al. Loss of heterozygosity of methylenetetrahydrofolate reductase in colon carcinomas. Oncol Rep. 1999;6:597-599.
56. Morrison K, Edwards YH, Lynch SA, et al. Methionine synthase and neural tube defects. J Med Genet. 1997;34:958-960.
57. Shaw GM, Todoroff K, Finnell RH, et al. Infant methionine synthase variants and risk for spina bifida. J Med Genet. 1999;36:86-87.
58. van der Put NMJ, van der Molen EF, Kluijtmans LAJ, et al. Sequence analysis of the coding region of human methionine synthase: relevance to hyperhomocysteinaemia in neural-tube defects and vascular disease. Q J Med. 1997;90:511-517.
59. Tsai MY, Welge BG, Hanson NQ, et al. Genetic causes of mild hyperhomocysteinemia in patients with premature occlusive coronary artery diseases. Atherosclerosis. 1999;143:163-170.
60. 12) increases risk for spina bifida. Mol Genet Metab. 1999;67:317-323.
61. Bostom AG, Silbershatz H, Rosenberg IH, et al. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med. 1999;159:1077-1080.
62. Vollset SE, Refsum H, Tverdal A, et al. Plasma total homocysteine and cardiovascular and noncardiovascular mortality: the Hordaland Homocysteine Study. Am J Clin Nutr. 2001;74:130-136.
63. Robinson K, Mayer EL, Miller DP, et al. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation. 1995;92:2825-2830.
64. Stubbs PJ, Al-Obaidi MK, Conroy RM, et al. Effect of plasma homocysteine concentration on early and late events in patients with acute coronary syndromes. Circulation. 2000;102:605-610.
65. Evans RW, Shaten BJ, Hempel JD, Cutler JA, Kuller LH. Homocysteine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol. 1997;17:1947-1953.
66. Nurk E, Tell GS, Vollset SE, et al. Plasma total homocysteine and hospitalizations for cardiovascular disease: the Hordaland Homocysteine Study. Arch Intern Med. 2002;162:1374-1381.
67. Abbate R, Sofi F, Brogi D, Marcucci R. Emerging risk factors for ischemic stroke. Neurol Sci. 2003;24(suppl 1):S11-S12.
68. Fallon UB, Virtamo J, Young I, et al. Homocysteine and cerebral infarction in Finnish male smokers. Stroke. 2003;34:1359-1363.
69. 6 but not homocyst(e)ine is associated with increased risk of stroke and transient ischemic attack in the era of folic acid grain fortification. Stroke. 2003;34:e5l-54.
70. Sacher Y, Soroker N, Motin M, et al. Blood homocysteine levels in stroke patients undergoing rehabilitation. Med Sci Monit. 2003;9:CR201-207.
71. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002;346:476-483.
72. McCaddon A, Davies G, Hudson P, Tandy S, Cattell H. Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry. 1998;13:235-239.
73. McCaddon A, Hudson P, Davies G, et al. Homocysteine and cognitive decline in healthy elderly. Dement Geriatr Cogn Disord. 2001;12:309-313.
74. 12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol. 1998;55:1449-1455.
75. Lopez O, Jagust WJ, Dulberg C, et al. Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study. Arch Neurol. 2003;60:1394-1399.
76. Lehmann M, Gottfries CG, Regland B. Identification of cognitive impairment in the elderly: homocysteine is an early marker. Dement Geriatr Cogn Disord. 1999;10:12-20.
77. Hoogeveen EK, Kostense PJ, Jakobs C, et al. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn Study. Circulation. 2000;101:1506-1511.
78. Wu LL, Wu JT. Hyperhomocysteinemia is a risk factor for cancer and a new potential tumor marker. Clin Chim Acta. 2002;322:21-28.
79. Zhu BT. Medical hypothesis: hyperhomocysteinemia is a risk factor for estrogen-induced hormonal cancer. Int J Oncol. 2003;22:499-508.
80. Oikawa S, Murakami K, Kawanishi S. Oxidative damage to cellular and isolated DNA by homocysteine: implications for carcinogenesis. Oncogene. 2003;22:3530-3538.
81. Durand P, Prost M, Loreau N, Lussier-Cacan S, Blache D. Impaired homocysteine metabolism and atherothrombotic disease. Lab Invest. 2001;81:645-672.
82. Kanani PM, Sinkey CA, Browning RL, et al. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation. 1999;100:1161-1168.
83. Chambers JC, McGregor A, Jean-Marie J, Obeid OA, Kooner JS. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy. Circulation. 1999;99:1156-1160.
84. Frei B. On the role of vitamin C and other antioxidants in atherogenesis and vascular dysfunction. Proc Soc Exp Biol Med. 1999;222:196-204.
85. Visioli F, Smith A, Zhang W, et al. Lipoic acid and vitamin C potentiate nitric oxide synthesis in human aortic endothelial cells independently of cellular glutathione status. Redox Rep. 2002;7:223-227.
86. McCully K, Ragsdale B. Production of arteriosclerosis by homocysteinemia. Am J Pathol. 1970;61:1-8.
87. McCully K, Wilson R. Homocysteine theory of arteriosclerosis. Atherosclerosis. 1975;22:215-227.
88. Welch G, Upchurch G, Loscalzo J. Homocysteine, oxidative stress and vascular disease. Hosp Pract. 1997;32:81-92.
89. Upchurch GJ, Welch G, Fabian A, et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem. 1997;272:17012-17017.
90. Starkekbaum G, Harlan J. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest. 1986;77:1370-1376.
91. Harker L, Harian J, Ross R. Effect of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons. Circ Res. 1983;53:731-739.
92. Stamler J, Loscallzo J. Endothelium-derived relaxing factor modulates the atherothrombogenic effects of homocysteine. J Cardiol Pharmacol. 1992;20:S202-S204.
93. Leoncini G, Pascale R, Signorello MG. Effects of homocysteine on L-arginine transport and nitric oxide formation in human platelets. Eur J Clin Invest. 2003;33:713-719.
94. Bilsborough W, Green DJ, Mamotte CD, et al. Endothelial nitric oxide synthase gene polymorphism, homocysteine, cholesterol and vascular endothelial function. Atherosclerosis. 2003;169:131-138.
95. Stuhlinger MC, Oka RK, Graf EE, et al. Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine. Circulation. 2003;108:933-938.
96. Wanby P, Brattstrom L, Brudin L, Hultberg B, Teerlink T. Asymmetric dimethylarginine and total homocysteine in plasma after oral methionine loading. Scand J Clin Lab Invest. 2003;63:347-353.
97. Jonasson TF, Hedner T, Hultberg B, Ohlin H. Hyperhomocysteinaemia is not associated with increased levels of asymmetric dimethylarginine in patients with ischaemic heart disease. Eur J Clin Invest. 2003;33:543-549.
98. Upchurch GJ, Welch G, Loscalzo J. Homocysteine EDRF and endothelial function. J Nutr. 1996;126:1290S-1294S.
99. Tsai J, Perrella M, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U S A. 1994;91:6369-6373.
100. Tsai J-C, Wang H, Perrella M, et al. Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. J Clin Invest. 1996;97:146-153.
101. Welch G, Upchurch G, Farivar R, et al. Homocysteine-induced nitric oxide production in vascular smooth muscle cells by NF-κB dependent transcriptional activation of Nos 2. Proc Am Assoc Phys. 1998;110:22-31.
102. Majors A, Ehrhart L, Pezacka E. Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol. 1997;17:2074-2081.
103. ras methylation in vascular endothelial cells by homocysteine but not cysteine. J Biol Chem. 199;272:25380-25385.
104. Harker L, Ross R, Slichter S, Scott C. Homocystine-induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis. J Clin Invest. 1976;58:731-741.
105. Di Minno G, Davi G, Margaglione M, et al. Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism. J Clin Invest. 1993;92:1400-1406.
106. Stamler J, Osborne J, Jaraki O, et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest. 1993;91:308-318.
107. Harpel P, Zhang X, Borth W. Homocysteine and hemostasis: pathogenetic mechanisms predisposing to thrombosis. J Nutr. 1996;126:1285S-1289S.
108. Durand P, Prost M, Blache D. Pro-thrombotic effects of a folic acid deficient diet in rat platelets and macrophages related to elevated homocysteine and decreased n-3 polyunsaturated fatty acids. Atherosclerosis. 1996;121:231-243.
109. Durand P, Lussier-Cacan S, Blache D. Acute methionine load induced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophage-derived tissue factor activity in rats. FASEB Lett. 1997;11:1157-1168.
110. Ratnoff O. Activation of Hageman factor by L-homocystine. Science. 1968;162:1007-1009.
111. Rodgers G, Conn M. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood. 1990;75:895-901.
112. Fryer R, Wilson B, Gubler D, Fitzgerald L, Rodgers G. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb Vasc Biol. 1993;13:405-410.
113. Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest. 1993;92:1381-1386.
114. Hajjar K, Mauri L, Jacovina A, et al. Tissue plasminogen activator binding to the annexin II tail domain. J Biol Chem. 1998;273:9987-9993.
115. Lentz S, Sadler J. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest. 1991;88:1906-1914.
116. Coppola A, Albisinni R, Madonna P, et al. Platelet and monocyte variables in homocystinuria due to cystathionine-beta-synthase deficiency. Haematologica. 1997;92:189-190.
117. Lentz S, Sobey C, Piegors D, et al. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inenia. J Clin Invest. 1996;98:24-29.
118. Weiss N. Mechanisms of increased vascular oxidant stress in hyperhomocysteinemia and its impact on endothelial function. Curr Drug Metab. 2005;6:27-36.
119. Topol G, Brunet A, Millanvoye E, et al. Homocysteine induces oxidative stress by uncoupling of NO synthase through reduction of tetrahydrobiopterin. Free Radic Biol Med. 2004;36:1532-1541.
120. Taha S, Azzi A, Ozer NK. Homocysteine induces DNA synthesis and proliferation of vascular smooth muscle cells by a hydrogen-peroxide-independent mechanism. Antioxid Redox Signal. 1999;Fall(3):365-369.
121. Chen C, Halkos ME, Surowiec SM, et al. Effects of homocysteine on smooth muscle cell proliferation in both cell culture and artery perfusion culture models. J Surg Rex. 2000;88(1):26-33.
122. McCully K. The Homocysteine Revolution. New Canaan, Conn: Keats Publishing Inc; 1997.
123. Wilcken D, Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J. Clin Invest. 1976;57:1079-1082.
124. Boushey C, Beresford S, Omenn G, Motulsky A. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA. 1995;274:1049-1057.
125. Graham I, Daly L, Refsum H, et al. Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA. 1997;277:1775-1781.
126. Kottke-Marchant K, Green R, Jacobsen D, et al. High plasma homocysteine: a risk factor for arterial and venous thrombosis in patients with normal coagulation profiles. Clin Appl Thromb Hemost. 1997;3:239-244.
127. Voutilainen S, Alfthan G, Nyyssonen K, Salonen R, Salonen J. Association between elevated plasma total homocysteine and increased common carotid artery wall thickness. Ann Med. 1998;30:300-306.
128. Genest JJ, McNamara JR, Salem DN, et al. Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol. 1990;16:1114-1119.
129. Brattstrom L, Lindgren A, Israelsson B, et al. Hyperhomocysteinaemia in stroke: prevalence cause, and relationships to type of stroke and stroke risk factors. Eur J Clin Invest. 1992;22:214-221.
130. Malinow MR, Nieto FJ, Sklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults: the Atherosclerosis in Communities (ARIC) Study. Circulation. 1993;87:1107-1113.
131. Selhub J, lacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med. 1995;332:286-291.
132. Robinson K, Arheart K, Refsum H, et al. for the European COMAC Group. Low circulating folate and vitamin B6 concentrations. Risk factors for stroke, peripheral vascular disease, and coronary artery disease. Circulation. 1998;97:437-443.
133. Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 1998;98:204-210.
134. Boers G, Smals A, Trijbels F, et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med. 1985;313:709-715.
135. Malinow M, Kang S, Taylor L, et al. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation. 1989;79:1180-1188.
136. Stampfer M, Malinow M, Willett W, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992;268:877-881.
137. Malinow M, Nieto F, Szklo M, Chambless L, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. Circulation. 1993;87:1107-1113.
138. Konechy N, Malinow M, Tunick P, et al. Correlation between plasma homocyst(e)ine and aortic atherosclerosis. Am Heart. 1997;133:534-540.
139. Wu L, Wu J, Hunt S, et al. Plasma homocyst(e)ine as a risk factor for early familial coronary artery disease. Clin Chem. 1994;40:552-561.
140. Hopkins P, Wu L, Wu J, et al. Higher plasma homocyst(e)ine and increased susceptibility to adverse effects of low folate in early familial coronary artery disease. Arterioscler Thromb Vasc Biol. 1995;15:1314-1320.
141. 6, pyridoxal phosphate, and folate. Am J Cardiol. 1995;75:1107-1111.
142. 12 and folate. Am J Epidemiol. 1996;143:845-859.
143. Verhoef P, Kok F, Kruyssen D, et al. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17:989-995.
144. Nygard O, Nordrehaug J, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;1337:230-236.
145. Wald N, Watt H, Law M, et al. Homocysteine and ischemic heart disease. Arch Intern Med. 1998;1158:862-867.
146. Alfthan G, Pekkanen J, Jauhiainen M, et al. Relation of serum homocysteine and lipoprotein (a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 1994;106:9-19.
147. Evans R, Shaten J, Hempel J, Cutler J, Kuller L. for the MRFIT Research Group. Homocyst(e)ine and risk of cardiovascular disease in the multiple risk factor intervention trial. Arterioscler Thromb Vasc Biol. 1997;17:1947-1953.
148. Folsom A, Nieto F, McGovern P, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins. Circulation. 1998;98:204-210.
149. Molgaard J, Malinow M, Lassvik C, et al. Hyperhomocyst(e)inemia: an independent risk factor for claudication. J Intern Med. 1992;231:273-279.
150. 6, from diet and supplements in relation to risk of coronary heart disease among women. JAMA. 1998;279:359-364.
151. Selhub J, Jacques P, Wilson P, Rush D, Rosenberg I. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 1993;270:2693-2698.
152. Donner MG, Klein GK, Mathes PB, Schandt P, Richter WO. Plasma total homocysteine levels in patients with early-onset coronary heart disease and low cardiovascular risk profile. Metabolism. 1998;47:273-279.
153. Kluijtmans LAJ, Kastelein JJP, Lindemans J, et al. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation. 1997;96:2573-2577.
154. Brattström L. Common mutation in the methylenetetrahydrofolate reductase gene offers no support for mild hyperhomocysteinemia being a causal risk factor for cardiovascular disease. Circulation. 1997;96:3805-3806.
155. Falcon C, Cattaneo M, Panzeri D, Martinelli I, Mannucci P. High prevalence of hyperhomocysteinemia with juvenile venous thrombosis. Arterioscler Thromb. 1994;14:1080-1083.
156. den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996;334:759-762.
157. den Heijer M, Brouwer I, Bos G, et al. Vitamin supplementation reduces blood homocysteine levels. A controlled trial in patients with venous thrombosis and healthy volunteers. Arterioscler Thromb Vasc Biol. 1998;18:356-361.
158. Simioni P, Prandoni P, Burlina A, et al. Hyperhomocysteinemia and deep-vein thrombosis: a case control study. Thromb Haemost. 1996;76:883-886.
159. Martinelli I, Cattaneo M, Panzeri D, Taioli E, Mannucci PM. Risk factors for primary deep vein thrombosis of the upper extremities. Ann Intern Med. 1997;126:707-711.
160. Eichinger S, Stümpfen A, Hirschl M, et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost. 1998;80:566-569.
161. den Heijer M, Blom HJ, Gerrits WBJ, Rosendaal FR, Bos GMJ. Hyperhomocysteinemia and venous thrombosis: a quantitative review. Thromb Haemost. 1997;532(suppl).
162. Fermo I, Vigano' D'Angelo V, Paroni R, et al. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med. 1995;123:747-753.
163. Ridker P, Hennekens C, Selhub J, et al. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation. 1997;95:1777-1782.
164. Legnani C, Palareti G, Grauso F, et al. Hyperhomocyst(e)mia and a common methylenetetrahydrofolate reductase mutation (Ala223Val MTHFR) in patients with inherited thrombophilic coagulation defects. Arterioscler Thromb Vasc Biol. 1997;17:2924-2929.
165. Arruda VR, von Zuben PM, Chiaparini LC, Annichino-Bizzacchi JM, Costa FF. The mutation ALA677→VAL in the methylenetetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. Thromb Haemost. 1997;77:818-821.
166. Salomon O, Dardik R, Zivelin A, et al. Homozygous methylenetetrahydrofolate reductase thermolability (MTHFR-T) is an independent risk factor for idiopathic deep-vein thrombosis (DVT) [abstract]. Thromb Haemost. June 1997;(suppl):568-569.
167. Margaglione M, D'Andrea G, d'Addedda M, et al. The methylenetetrahydrofolate reductase TT677 genotype is associated with venous thrombosis independently of the coexistence of the FV Leiden and the prothrombin A20210 mutation. Thromb Haemost. 1998;79:907-911.
168. De Stefano V, Casorelli I, Rossi E, et al. Interaction between hyperhomocysteinemia and inherited thrombophilic factors in venous thromboembolism. Semin Thromb Hemost. 2000;26:305-311.
169. Trillot N, Preudhomme C, Alhenc-Gelas M, et al. Thermolabile methylenetetrahydrofolate reductase (MTHFR) does not modify the risk for venous thromboembolism in subjects with heterozygous factor V Leiden. Blood. 1996;10(suppl 1):284a.
170. Cattaneo M, Monzani ML, Martinelli I, Falcon CR, Mannucci PM. Interelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation. 1998;52(suppl):S21.
171. Cattaneo M, Tsai MY, Bucciarelli P, et al. A common mutation in the methylenetetrahydrofolate reductase gene (C677T) increases the risk for deep-vein thrombosis in patients with mutant factor V (factor V:Q506). Arterioscler Thromb Vasc Biol. 1997;17:1662-1666.
172. Kluijtmans LAJ, den Heijer M, Reitsma PH, et al. Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep-vein thrombosis. Thromb Haemost. 1998;79:254-258.
173. Kluijtmans L, Boers G, Verbruggen B, et al. Homozygous cystathionine β-synthase deficiency, combined with factor V Leiden or thermolabile methylenetetrahydrofolate reductase in the risk of venous thrombosis. Blood. 1998;91:2015-2018.
174. Lalouschek W, Aull S, Korninger L, et al. 677C to T mutation in the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene and plasma homocyst(e)ine levels in patients with TIA or minor stroke. Neurol Sci. 1998;155:156-162.
175. Bonaa KH, Njølstad I, Ueland PM, et al. Homocysteine lowering and
176. Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, et al. Secondary prevention with folic acid: effects on clinical outcomes. J Am Coll Cardiol. 2003;12:2105-2113.
177. Baker F, Picton D, Blackwood S, et al. Blinded comparison of folic acid and placebo in patients with ischemic heart disease: an outcome trial [abstract]. Circulation. 2002;106(suppl II):741.
178. Lange H, Suryapranata H, De Luca G, et al. Folate therapy and in stent restenosis after coronary stenting. N Engl J Med. 2004;26:2673-2681.
179. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death. The Vitamin Intervention for Stroke Prevention (VISP) Randomized Controlled Trial. JAMA. 2005;5:565-575.
180. Lewis SJ, Ebrahim S, Smith GD. Meta-analysis of MTHFR 677C→T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? BMJ. 2005;331:1053.
181. Williams C, Kingwell BA, Burke K, McPherson J, Dart AM. Folic acid supplementation for 3 weeks reduces pulse pressure and large artery stiffness independent of MTHFR phenotype. Am J Clin Nutr. 2005;82:26-31.
182. Assanelli D, Bonanome A, Pezzini A, et al. Folic acid and vitamin E supplementation effects on homocysteinemia, endothelial function and plasma anti-oxidant capacity in young myocardial infarction patients. Pharmacol Res. 2004;49:79-84.
183. Stott DJ, MacIntosh G, Lowe G, et al. Randomized controlled trial of homocysteine-lowering vitamin treatment in elderly patients with vascular disease. Am J Clin Nutr. 2005;82:1320-1326.
184. Nurk E, Refusm H, Tell GS, et al. Plasma total homocysteine and memory in the elderly: the Hordaland Homocysteine Study. Ann Neurol. 2005;6:847-857.
185. Silaste M, Rantala M, Alfthan G, et al. Plasma homocysteine concentration is decreased by dietary intervention. Br J Nutr. 2003;89:295-301.
186. Steenge GR, Verhoef P, Katan MB. Betaine supplementation lowers plasma homocysteine in healthy men and women. J Nutr. 2003;133:1291-1295.
187. Brouwer IA, Verhoef P, Urgert R. Betaine supplementation and plasma homocysteine in healthy volunteers. Arch Intern Med. 2000;160:2546-2547.
188. Schwab U, Torronen A, Toppinen L, et al. Betaine supplementation decreases plasma homocysteine concentrations but do not affect body weight, body composition, or resting energy expenditure in human subjects. Am J Clin Nutr. 2002;76:961-967.
189. Ventura P, Panini R, Abbati G, et al. Urinary and plasma homocysteine and cysteine levels during prolonged oral N-acetylcysteine therapy. Pharmacology. 2003;68:1005-1014.
190. Carmel R, Jacobsen DW. Homocysteine in Health & Disease. New York, NY: Cambridge University Press; 2001.
191. Fryer RH, Wilson BD, Gubler DB, et al. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb. 1993;13:1327-1333.
192. Munnich A, Saudubray J-M, Dautzenberg M-D, et al. Diet-responsive proconvertin (factor VII) deficiency in homocystinuria. J. Pediatr. 1983;102:730-734.
193. Al-Obaidi MK, Philippou H, Stubbs PJ, et al. Relationships between homocysteine, factor VIIa, and thrombin generation in acute coronary syndromes. Circulation. 2000;101:372-377.
194. Charlot JC, Haye C, Chaumien JP. Homocystinurie et deficit en facteur VII. Bull Soc Ophthalmol Fr. 1982;82:787-789.
195. Undas A, Domagala TB, Jankowski M, et al. Treatment of hyperhomocysteinemia with folic acid and vitamin B12 and B6 attenuates thrombin generation. Thromb Res. 1999;95:281-288.
196. Domagala TB, Undas A, Celinska-Lowenhoff M, et al. Thrombin generation in response to methionine loading test in patients with ischemic heart disease [poster]. J Thromb Haemost. 2003;1(suppl 1):P0435.
197. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest. 1991;88:1901-1914.
198. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest. 1986;77:1909-1916.
199. Sauls DL, Wolberg As, Hoffman M. Elevated plasma homocysteine leads to alterations in fibrin clot structure and stability: implications for the mechanism of thrombosis in hyperhomocysteinemia. J Thromb Haemost. 2003;1:300-306.
200. Lauricella AM, Quintana IL, Kordich LC. Effects of homocysteine thiol group on fibrin networks: another possible mechanism of harm. Thromb Res. 2002;107:75-79.
201. Hayashi T, Honda G, Suzuki K. An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood. 1992;79:2930-2936.
202. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood. 1990;75:895-901.
203. Undas A, Williams EB, Butenas S, et al. Homocysteine inhibits inactivation of factor Va by activated protein C. J Biol Chem. 2001;276:4389-4397.
204. Lentz SR, Piegors DJ, Fernandez JA, et al. Effect of hyperhomocysteinemia on protein C activation and activity. Blood. 2002;100:2108-2112.
205. Zarychanski R, Houston DS. Plasma homocysteine concentration is not associated with activated protein C resistance in patients investigated for hypercoagulability. Thromb Haemost. 2004;91:1115-1122.
206. Marcucci R, Prisco D, Brunelli T, et al. Tissue factor and homocysteine levels in ischemic heart disease are associated with angiographically documented clinical recurrences after coronary angioplasty. Thromb Haemost. 2000;83:826-832.
207. Cella G, Burlina A, Sbarai A, et al. Tissue factor pathway inhibitor levels in patients with homocystinuria. Thromb Res. 2000;98:375-381.
208. Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest. 1993;91:2873-2879.
209. Tofler GH, D'Agostine RB, Jacques PF, et al. Association between increased homocysteine levels and impaired fibrinolytic potential: potential mechanism for cardiovascular risk. Thromb Haemost. 2002;88:799-804.
210. Harpel PC, Change VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis and sulfhydryl compound metabolism. Proc Natl Acad Sci U S A. 1992;89:10193-10197.
211. Bonaa KH, for the Norwegian Vitamin (NORVIT) Study Group. NORVIT: randomized trial of homocysteine-lowering with B vitamins for secondary prevention of cardiovascular disease after acute myocardial infarction. Presented at the European Society of Cardiology Congress, Stockholm, Sweden, September 3-7, 2005.